A Randomised, Phase I, Single Dose, Placebo-Controlled, Dose Escalation Study of TB-402, A Monocloncal Antibody Directed Against FACTOR VIII, Administered Intravenously in Healthy Male Volunteers

Trial Profile

A Randomised, Phase I, Single Dose, Placebo-Controlled, Dose Escalation Study of TB-402, A Monocloncal Antibody Directed Against FACTOR VIII, Administered Intravenously in Healthy Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2010

At a glance

  • Drugs TB 402 (Primary)
  • Indications Thrombosis; Venous thrombosis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors ThromboGenics
  • Most Recent Events

    • 11 Dec 2007 Results will be presented at the 49th annual meeting of the American Society of Hematology (ASH).
    • 10 Dec 2007 Results presented at ASH 2007
    • 10 Sep 2007 Status changed to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top